BMS-820836

DRUG6 trials

Sponsors

Bristol-Myers Squibb

Conditions

Depression

Phase 1

Multiple-Ascending Dose Study

CompletedNCT00892840

Bristol-Myers SquibbDepression

Start: 2009-05-31End: 2010-11-30Updated: 2011-02-11

Single Dose Study of BMS-820836

CompletedNCT00964912

Bristol-Myers SquibbDepression

Start: 2008-07-31End: 2009-04-30Updated: 2011-01-25

Japanese Phase 1 Multiple Ascending Dose (MAD) Study

CompletedNCT01396252

Bristol-Myers SquibbDepression

Start: 2011-09-30End: 2012-05-31Updated: 2013-06-10

Phase 2

Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

CompletedNCT01309945

Bristol-Myers SquibbDepression

Start: 2011-04-30End: 2013-01-31Updated: 2015-10-12

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

TerminatedNCT01361555

Bristol-Myers SquibbDepression

Start: 2011-08-31End: 2013-10-31Updated: 2015-10-12

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

CompletedNCT01369095

Bristol-Myers SquibbDepression

Start: 2011-07-31End: 2013-05-31Updated: 2015-10-12

Related Papers

Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836.

2014-08-148 citations